A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years

NCT ID: NCT00638092

Last Updated: 2015-05-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1275 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 μg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed as a UK multicentre randomised controlled trial to establish whether iodine supplementation of preterm infants benefits neurodevelopment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transient Hypothyroxinemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Iodine

This is the hypothetical active arm

Group Type EXPERIMENTAL

sodium iodide

Intervention Type DRUG

sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation

Placebo

this is the hypothetical placebo

Group Type PLACEBO_COMPARATOR

Sodium Chloride

Intervention Type DRUG

Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sodium iodide

sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation

Intervention Type DRUG

Sodium Chloride

Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All infants born under 31 weeks gestation

Exclusion Criteria

* Mother exposed to excess iodine during pregnancy or delivery
Minimum Eligible Age

1 Hour

Maximum Eligible Age

42 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Dundee

OTHER

Sponsor Role collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

Sponsor Role collaborator

University of Oxford

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fiona Williams, Dr

Role: STUDY_DIRECTOR

University of Dundee

Peter Brocklehurst, Professor

Role: STUDY_CHAIR

UCL

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ninewells Hospital and Medical School

Dundee, Tayside, United Kingdom

Site Status

Royal Maternity Hospital

Belfast, , United Kingdom

Site Status

Heartlands Hospital

Birmingham, , United Kingdom

Site Status

University Hospital Coventry

Coventry, , United Kingdom

Site Status

Derbyshire Childrens Hospital

Derby, , United Kingdom

Site Status

Princess Royal Maternity Hospital

Glasgow, , United Kingdom

Site Status

Southern General Hospital

Glasgow, , United Kingdom

Site Status

Crosshouse Hospital

Kilmarnock, , United Kingdom

Site Status

Leicester Royal Infirmary

Leicester, , United Kingdom

Site Status

Altnagelvin Area Hospital

Londonderry, , United Kingdom

Site Status

James Cook University Hospital

Middlesbrough, , United Kingdom

Site Status

Royal Victoria Infirmary

Newcastle upon Tyne, , United Kingdom

Site Status

Nottingham City Hospital

Nottingham, , United Kingdom

Site Status

Queen's Medical Centre

Nottingham, , United Kingdom

Site Status

Royal Berkshire Hospital

Reading, , United Kingdom

Site Status

Jessops Wing Hospital

Sheffield, , United Kingdom

Site Status

University Hospital of North Tees

Stockton-on-Tees, , United Kingdom

Site Status

Sunderland City Hospitals

Sunderland, , United Kingdom

Site Status

Wishaw General Hospital

Wishaw, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Williams F, Hume R, Ogston S, Brocklehurst P, Morgan K, Juszczak E; I2S2 team. A summary of the iodine supplementation study protocol (I2S2): a UK multicentre randomised controlled trial in preterm infants. Neonatology. 2014;105(4):282-9. doi: 10.1159/000358247. Epub 2014 Feb 27.

Reference Type BACKGROUND
PMID: 24576827 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.euthyroid.org

Supports programme of work

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-001024-31

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

08/S0501/31

Identifier Type: OTHER

Identifier Source: secondary_id

09/800/03

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

08/S0501/31

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Novel Approaches to the Treatment of Hypothyroidism
NCT06731764 RECRUITING PHASE2/PHASE3